World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
74
Citations
21695
World Ranking
19371
National Ranking
1015

Overview

Ulrich Dührsen is affiliated with the University of Duisburg-Essen in Germany and has contributed extensively to the field of medicine, with a total of 210 publications. Their research primarily focuses on several subfields including pathology and forensic medicine, radiology, nuclear medicine and imaging, oncology, genetics, and pulmonary and respiratory medicine.

Their main research topics include lymphoma diagnosis and treatment, medical imaging techniques and applications, radiomics and machine learning in medical imaging, CNS lymphoma diagnosis and treatment, chronic lymphocytic leukemia research, CAR-T cell therapy research, and acute myeloid leukemia research.

Frequent publication venues for Dührsen's work include:

  • Blood
  • Blood Advances
  • Scientific Reports
  • Leukemia
  • Hematological Oncology

Among recent publications, notable papers include:

  • Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA, 2021, Nature Biotechnology
  • Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index, 2022, Journal of Clinical Oncology
  • Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas, 2022, Cancer Cell
  • Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma, 2021, British Journal of Haematology
  • Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma, 2021, Journal of Clinical Oncology

Collaborations have played a significant role in Dührsen's research output. Frequent co-authors include Andreas Hüttmann, Christine Hanoun, Pieternella J. Lugtenburg, Ronald Boellaard, and Josée M. Zijlstra.

Best Publications

  • A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

    Eva Hoster;Martin Dreyling;Wolfram Klapper;Christian Gisselbrecht

  • Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)

    Georg Lenz;Martin Dreyling;Eva Hoster;Bernhard Wörmann

  • Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.

    Peter Hillmen;Petra Muus;Ulrich Dührsen;Antonio M. Risitano

  • Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

    Anas Younes;Laurie H. Sehn;Peter Johnson;Pier Luigi Zinzani

  • Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

    Kai Neben;Henk M. Lokhorst;Anna Jauch;Uta Bertsch

  • Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network

    Olivier Hermine;Olivier Hermine;Eva Hoster;Jan Walewski;André Bosly

  • Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma

    David M. Kurtz;Florian Scherer;Florian Scherer;Michael C. Jin;Joanne Soo

  • A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia.

    Walter Fiedler;Rolf Mesters;Heike Tinnefeld;Sonja Loges

  • Acute Myelogenous Leukemia-Induced Sympathetic Neuropathy Promotes Malignancy in an Altered Hematopoietic Stem Cell Niche

    Maher Hanoun;Dachuan Zhang;Toshihide Mizoguchi;Sandra Pinho

  • Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group

    Stephan Stilgenbauer;Thorsten Zenz;Dirk Winkler;Andreas Bühler

  • Inflammatory reactions and severe neutropenia in mice lacking the transcriptional repressor Gfi1.

    Holger Karsunky;Hui Zeng;Thorsten Schmidt;Branko Zevnik

  • An Observational Study of Anaemia Management in Patients with NHL Receiving CHOP-14 or -21 (With or Without Rituximab)

    Gregor Verhoef;Hans E Johnsen;Francesca Gaia Rossi;Antonio Salar

  • Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.

    Uwe Platzbecker;Jan Moritz Middeke;Katja Sockel;Regina Herbst

  • Rituximab Maintenance Therapy After Autologous Stem-Cell Transplantation in Patients With Relapsed CD20+ Diffuse Large B-Cell Lymphoma: Final Analysis of the Collaborative Trial in Relapsed Aggressive Lymphoma

    Christian Gisselbrecht;Norbert Schmitz;Nicolas Mounier;Devinder Singh Gill

  • Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial

    Dieter Hoelzer;Jan Walewski;Hartmut Döhner;Andreas Viardot

  • CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia.

    J Dürig;M Naschar;U Schmücker;K Renzing-Köhler

  • ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia

    J Dürig;H Nückel;M Cremer;A Führer

  • Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).

    Oliver G. Ottmann;Barbara Wassmann;Heike Pfeifer;Aristoteles Giagounidis

  • Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia.

    R Schroers;F Griesinger;L Trümper;D Haase

  • Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study.

    E Van Den Neste;N Schmitz;N Mounier;D Gill

Frequent Co-Authors

Ludger Klein-Hitpass
Ludger Klein-Hitpass University of Duisburg-Essen
Tarik Möröy
Tarik Möröy University of Montreal
Karl-Heinz Jöckel
Karl-Heinz Jöckel University of Duisburg-Essen
Martin Dreyling
Martin Dreyling Ludwig-Maximilians-Universität München
Ralf Küppers
Ralf Küppers University of Duisburg-Essen
Hartmut Döhner
Hartmut Döhner University of Ulm
Davide Rossi
Davide Rossi European Society for Medical Oncology
Reiner Siebert
Reiner Siebert University of Ulm
Wolfram Klapper
Wolfram Klapper Kiel University
Hubert Schrezenmeier
Hubert Schrezenmeier University of Ulm

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in healthcare careers beyond traditional medical school? There are several flexible and affordable online paths to enter the medical field. For example, earning a pharmacy degree online can help you become a licensed pharmacist, opening doors to clinical and research roles.

If you are more interested in healthcare technology and administration, accredited rhit programs online train you in managing patient records and healthcare information systems.

For those looking for a quicker entry into the medical field, consider a low cost medical coding and billing online program. These programs prepare you for essential roles supporting clinics, hospitals, and insurance companies.

Nursing is another rewarding pathway. The cheapest online fnp program offers an affordable route for nurses to become family nurse practitioners with advanced patient care responsibilities.

Each of these online degrees offers strong job prospects and flexible study options, making them excellent alternatives or complementary pathways to studying medicine in the USA.

Best Scientists Citing Ulrich Dührsen

Trending Scientists

Recently Published Articles